Skip to main content

ADVANCE

Accelerated Development of VAcciNe outcome research Collaboration in Europe

The ADVANCE vision is focused on timely and best evidence on vaccine effects. The mission is to establish a Blueprint for a validated and tested best practice framework that could rapidly provide robust data on vaccine benefits and risks to support accelerated decision making.

This is a EU-funded collaboration between researchers, public health and industry with the aim to build an integrated and sustainable framework for continuous vaccine effect monitoring in order to evaluate the benefit-risk of vaccines and to maintain public trust in Europe.
In Europe there is a need to achieve continuous benefit risk assessment throughout the life cycle of vaccines. This would encompass: Rapid verification of safety issues with a prior hypothesis utilizing all available information sources (e.g. clinical trial data, spontaneous reporting data, data from electronic health care record; Thorough signal substantiation (hypothesis testing studies); Effectiveness of vaccine utilizing available data sources (e.g. clinical trial data, pathogen/vaccine targeted disease surveillance data and data from electronic health care records); Population impact assessment of intended vaccine effect utilizing available data sources (e.g. clinical trial data, pathogen/vaccine targeted disease surveillance data, data from electronic health care records); Integrated vaccine benefit-risk assessment with the option for cyclical updates during the vaccine life cycle.
This collaboration commenced during the latter half of 2013 and is funded for 5 years.

Project leader

Project period: 2013-2018
Main financing: EU